Show source-provided references
1. Jin, R., Luo, L., and Zheng, J. (2022). The Trinity of skin: Skin homeostasis as a neuro-endocrine-immune organ. Life, 12.
10.3390/life12050725 ↗2. Nguyen, A.V., and Soulika, A.M. (2019). The dynamics of the skin’s immune system. Int. J. Mol. Sci., 20.
10.3390/ijms20081811 ↗3. Li, C., Kuai, L., Cui, R., and Miao, X. (2022). Melanogenesis and the targeted therapy of melanoma. Biomolecules, 12.
10.3390/biom12121874 ↗4. Thawabteh, A.M., Jibreen, A., Karaman, D., Thawabteh, A., and Karaman, R. (2023). Skin pigmentation types, causes and treatment—A review. Molecules, 28.
10.20944/preprints202305.0751.v1 ↗9. Hyperpigmentation therapy: A review
10. Pigmentary disorders, prevalence, impact on quality of life and social stigmatization: Results of the first large international survey
10.1016/j.jaad.2024.07.1114 ↗14. Ghasemiyeh, P., Fazlinejad, R., Kiafar, M.R., Rasekh, S., Mokhtarzadegan, M., and Mohammadi-Samani, S. (2024). Different therapeutic approaches in melasma: Advances and limitations. Front. Pharmacol., 15.
10.3389/fphar.2024.1337282 ↗16. The potential role of antioxidants in mitigating skin hyperpigmentation resulting from ultraviolet and visible light-induced oxidative stress
10.1111/phpp.12423 ↗19. Qu, Y., Wang, S., Xie, H., Meng, X., Cui, B., and Xiao, Z. (2025). Melasma secondary to drugs: A real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS). BMC Pharmacol. Toxicol., 26.
10.1186/s40360-025-00912-4 ↗20. A focused review on the pathophysiology of post-inflammatory hyperpigmentation
10.1111/pcmr.13038 ↗23. Lawrence, E., Syed, H.A., and Al Aboud, K.M. (2025, November 15). Postinflammatory hyperpigmentation, StatPearls, Available online: https://www.ncbi.nlm.nih.gov/books/NBK559150/.
28. Camayo, T.V., Lee, V.R., and Zhou, X.A. (2025, November 16). Drug-induced pigmentation, StatPearls, Available online: https://www.ncbi.nlm.nih.gov/books/NBK542253/.
29. Arni, C., and Preclaro, I. (2023). Drug-induced pigmentation. Pigmentation Disorders—Etiology and Recent Advances in Treatments, IntechOpen.
10.5772/intechopen.108680 ↗30. Novel preventive and therapeutic strategies for ephelides (freckles) from a Persian medicine perspective: A narrative review
10.5812/jssc-123335 ↗31. Pigmentation disorders: Diagnosis and management
32. Couteau, C., and Coiffard, L. (2016). Overview of skin whitening agents: Drugs and cosmetic products. Cosmetics, 3.
10.3390/cosmetics3030027 ↗33. Skin lightening & management of hyperpigmentation
34. Topical hydroquinone for hyperpigmentation: A narrative review
35. Burger, P., Landreau, A., Azoulay, S., Michel, T., and Fernandez, X. (2016). Skin whitening cosmetics: Feedback and challenges in the development of natural skin lighteners. Cosmetics, 3.
10.3390/cosmetics3040036 ↗37. Phasha, V., Senabe, J., Ndzotoyi, P., Okole, B., Fouche, G., and Chuturgoon, A. (2022). Review on the use of Kojic Acid—A skin-lightening ingredient. Cosmetics, 9.
10.3390/cosmetics9030064 ↗38. Petrovici, A.-G., Spennato, M., Bîtcan, I., Péter, F., Cotarcă, L., Todea, A., and Ordodi, V.L. (2025). A comprehensive review of azelaic acid pharmacological properties, clinical applications, and innovative topical formulations. Pharmaceuticals, 18.
10.3390/ph18091273 ↗39. Comparative study on depigmenting agents in skin of color
40. Postinflammatory hyperpigmentation: A review of the epidemiology, clinical features, and treatment options in skin of color
41. Chambers, C. (2008). Opinion on Kojic Acid, Scientific Committee on Consumer Products.
46. Fan, M., Fan, X., Lai, Y., Chen, J., Peng, Y., Peng, Y., Xiang, L., and Ma, Y. (2024). Protease-Activated Receptor 2 in inflammatory skin disease: Current evidence and future perspectives. Front. Immunol., 15.
10.3389/fimmu.2024.1448952 ↗51. The antityrosinase and antioxidant activities of flavonoids dominated by the number and location of phenolic hydroxyl groups
10.1186/s13020-018-0206-9 ↗52. Augmented glutathione absorption from oral mucosa and its effect on skin pigmentation: A clinical review
10.2147/CCID.S378470 ↗54. An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women
10.1111/ijd.12999 ↗55. Peng, X., Ma, Y., Yan, C., Wei, X., Zhang, L., Jiang, H., Ma, Y., Zhang, S., Xing, M., and Gao, Y. (2024). Mechanism, formulation, and efficacy evaluation of natural products for skin pigmentation treatment. Pharmaceutics, 16.
10.3390/pharmaceutics16081022 ↗56. Singh, S., Sharma, N., Zahoor, I., Behl, T., Antil, A., Gupta, S., Anwer, M.K., Mohan, S., and Bungau, S.G. (2022). Decrypting the potential of nanotechnology-based approaches as cutting-edge for management of hyperpigmentation disorder. Molecules, 28.
10.3390/molecules28010220 ↗59. Roselan, M.A., Ashari, S.E., Faujan, N.H., Mohd Faudzi, S.M., and Mohamad, R. (2020). An improved nanoemulsion formulation containing kojic monooleate: Optimization, characterization and in vitro studies. Molecules, 25.
10.3390/molecules25112616 ↗61. Madawi, E.A., Al Jayoush, A.R., Rawas-Qalaji, M., Thu, H.E., Khan, S., Sohail, M., Mahmood, A., and Hussain, Z. (2023). Polymeric nanoparticles as tunable nanocarriers for targeted delivery of drugs to skin tissues for treatment of topical skin diseases. Pharmaceutics, 15.
10.3390/pharmaceutics15020657 ↗62. Inhibitory effect of the water-soluble polymer-wrapped derivative of fullerene on UVA-induced melanogenesis via downregulation of tyrosinase expression in human melanocytes and skin tissues
10.1007/s00403-007-0740-2 ↗65. Microneedling-assisted delivery of metformin versus tranexamic acid in treating melasma: A randomized controlled study
10.1186/s40001-025-03032-1 ↗66. Evaluation of the effectiveness of microneedling with tranexamic acid in comparison with microneedling with vitamin C in the treatment of melasma: A prospective and single-blind clinical trial
10.1002/hsr2.1636 ↗68. Wang, T., Wang, Y., Wang, J., Chen, H., Qu, B., and Li, Z. (2021). Efficacy and safety of topical therapy with botanical products for Melasma: A systematic review and meta-analysis of randomized controlled trials. Front. Med., 8.
10.3389/fmed.2021.797890 ↗